In addition, after including three studies that provided 2-year OS data and two studies with 4-year OS [4, 11, 12, 29] for the pooled analysis of 2-year OS, the pooled RRs showed a minor variation similar to that of the pooled analysis of the 5-year OS, indicating that our results on the impact of KIT mutations on the OS of CBF-AML and its subgroups are fairly robust. The gene discussed is KIT; the disease is acute myeloid leukemia.